KRAS and cancer: The selectivity and potency of 12VC1 allowed us to perform proof-of-concept evaluation on whether a mutant-selective, noncovalent reagent can effectively inhibit the growth of cancer cells driven by endogenous KRAS mutants by using monobodies as genetically encoded, intracellular reagents32,33.